Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03319628
Previous Study | Return to List | Next Study

First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03319628
Recruitment Status : Recruiting
First Posted : October 24, 2017
Last Update Posted : May 3, 2021
Sponsor:
Collaborator:
IQVIA Biotech
Information provided by (Responsible Party):
Mersana Therapeutics

Brief Summary:
First-in-human, Phase 1b/2 safety study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks. Patients with tumor types likely to express NaPi2b were enrolled in dose escalation. Patients with platinum-resistant ovarian cancer and non-small cell lung cancer (adenocarcinoma subtype) are being enrolled in the expansion segment of this study. Patients with platinum-resistant, high-grade serous ovarian cancer are being enrolled in the UPLIFT segment of this study. In addition to safety assessments, the pharmacokinetics of the drug will be assessed along with ADC activity.

Condition or disease Intervention/treatment Phase
Platinum Resistant Ovarian Cancer Non Small Cell Lung Cancer Metastatic Drug: upifitamab rilsodotin Phase 1 Phase 2

Detailed Description:
This is a multi-center study of XMT-1536 (upifitamab rilsodotin) in patients with tumors likely to express NaPi2b, focusing on patients with platinum-resistant ovarian cancer and non-small cell lung cancer, adenocarcinoma subtype. XMT-1536 (upifitamab rilsodotin) will be administered as an intravenous infusion once every four weeks. The study consists of three segments: dose escalation (DES), dose expansion (EXP), and the pivotal cohort (UPLIFT). The DES segment studied small groups of patients who received increased doses. A Safety Review Committee was established to review the data from each dose level before moving to the next higher dose. The dose escalation cohort has ended and is no longer enrolling patients. Enrollment into the EXP segment consists of 2 parallel cohorts of patients to confirm the dose that has been identified in DES and estimate the objective response rate in each patient population. Enrollment into the pivotal cohort (UPLIFT) includes patients with platinum-resistant ovarian cancer. All adverse events will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria version (CTCAE v5.0). Throughout the study, pharmacokinetics will be measured using proprietary assays developed by Mersana. Anti-cancer activity will be measured via RECIST.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 420 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Open-label, dose escalation to reach MTD. The MTD will be confirmed in parallel cohorts: patients with platinum-resistant ovarian cancer; patients with non-squamous NSCLC, adenocarcinoma subtype
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Actual Study Start Date : December 12, 2017
Estimated Primary Completion Date : July 31, 2022
Estimated Study Completion Date : December 31, 2022


Arm Intervention/treatment
Experimental: Dose Escalation

XMT-1536 (upifitamab rilsodotin) treatment is administered in groups of patients who will receive doses that increase over time.

This cohort is closed to enrollment.

Drug: upifitamab rilsodotin
XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.
Other Names:
  • XMT-1536
  • UpRi

Experimental: Dose Expansion - Ovarian Cancer

Once the maximum tolerated dose or recommended Phase 2 dose is achieved in dose escalation, new groups of patients will receive XMT-1536 (upifitamab rilsodotin) at this fixed-dose.

Patients with ovarian cancer will enroll until sites approve UPLIFT.

Drug: upifitamab rilsodotin
XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.
Other Names:
  • XMT-1536
  • UpRi

Experimental: Dose Expansion - NSCLC adenocarcinoma
Once the maximum tolerated dose or recommended Phase 2 dose is achieved in dose escalation, new groups of patients will receive XMT-1536 (upifitamab rilsodotin) at this fixed-dose.
Drug: upifitamab rilsodotin
XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.
Other Names:
  • XMT-1536
  • UpRi

Experimental: Pivotal Cohort (UPLIFT)
Patients with platinum-resistant ovarian cancer will receive the recommended Phase 2 dose of XMT-1536 (upifitamab rilsodotin) to further confirm the efficacy
Drug: upifitamab rilsodotin
XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.
Other Names:
  • XMT-1536
  • UpRi




Primary Outcome Measures :
  1. DES: Maximum tolerated dose or recommended Phase 2 dose [ Time Frame: Up to 36 weeks, from the date of first dose until unacceptable side effects or a dose-limiting toxicity is met ]
    Evaluate adverse events and concomitant medication use after XMT-1536 (upifitamab rilsodotin) doses

  2. DES and EXP: Safety and Tolerability [ Time Frame: First dose up until 30 days after study termination ]
    Evaluate incidence and severity of adverse events

  3. EXP: Anti-neoplastic effects of XMT-1536 (upifitamab rilsodotin) [ Time Frame: Every 6 weeks for up to 36 weeks ]
    Monitor tumor size

  4. UPLIFT: Investigator-assessed objective response rate (ORR) of XMT-1536 (upifitamab rilsodotin) in the ITT-Higher NaPi2b population [ Time Frame: Every 8 weeks until disease progression or up to 24 months ]
    Confirmed ORR is defined as the proportion of patients who have achieved a confirmed complete response (CR) or partial response (PR) per RECIST v1.1 after the initiation of study treatment.


Secondary Outcome Measures :
  1. DES and EXP: Time of maximum observed concentration of XMT-1536 (upifitamab rilsodotin) [ Time Frame: Daily for one week after first dose; weekly until 28 days after first dose; immediately before and after and 1 week after all subsequent doses ]
    Determine the pharmacokinetics of XMT-1536 (upifitamab rilsodotin)

  2. DES and EXP: Maximum concentration of XMT-1536 (upifitamab rilsodotin) [ Time Frame: Daily for one week after first dose; weekly until 28 days after first dose; immediately before and after and 1 week after all subsequent doses ]
    Determine the pharmacokinetics of XMT-1536 (upifitamab rilsodotin)

  3. DES and EXP: Area under the concentration curve of the last measurable concentration of XMT-1536 (upifitamab rilsodotin) [ Time Frame: Daily for one week after first dose; weekly until 28 days after first dose; immediately before and after and 1 week after all subsequent doses ]
    Determine the pharmacokinetics of XMT-1536 (upifitamab rilsodotin)

  4. DES: Anti-neoplastic effects of XMT-1536 (upifitamab rilsodotin) [ Time Frame: Every 6 weeks for up to 36 weeks ]
    Monitor tumor size

  5. DES and EXP: Anti-drug antibody and neutralizing antibody [ Time Frame: Every 6 weeks for up to 36 weeks ]
    Analyze blood for antibodies to XMT-1536 (upifitamab rilsodotin) and neutralizing antibodies

  6. UPLIFT: Investigator-assessed objective response rate of XMT-1536 (upifitamab rilsodotin) regardless of NaPi2b expression [ Time Frame: Every 8 weeks until disease progression or up to 24 months ]
    Assess the investigator-assessed objective response rate of XMT-1536 (upifitamab rilsodotin) regardless of NaPi2b expression

  7. UPLIFT: Objective response rate by independent radiology review (IRR) for patients with higher NaPi2b and overall [ Time Frame: Every 8 weeks until disease progression or up to 24 months ]
    Assess the objective response rate by IRR for patients with higher NaPi2b and overall

  8. UPLIFT: Duration of objective response (DOR) [ Time Frame: 4 weeks after first response and every 8 weeks until disease progression or up to 24 months ]
    Assess the duration of objective response (DOR) in patients who achieve a response

  9. UPLIFT: Incidence and severity of adverse events [ Time Frame: First dose up until 60 days after study termination ]
    Evaluate incidence and severity of adverse events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

General Inclusion Criteria (for Dose Escalation, Expansion, and UPLIFT):

  • ECOG performance status 0 or 1
  • Measurable disease as per RECIST, version 1.1
  • Resolution of all acute toxic effects of prior therapy or surgical procedures to ≤Grade 1 (except alopecia, stable immune-related toxicity such as hypothyroidism on hormone replacement, adrenal insufficiency on ≤10 mg daily prednisone [or equivalent], chronic Grade 2 peripheral sensory neuropathy after prior taxane therapy).
  • Cardiac left ventricular ejection fraction (LVEF) ≥50% or ≥ the institution's lower limit of normal by either Echo or MUGA scan
  • Adequate organ function as defined by the following criteria:

    1. Absolute neutrophil count (ANC) ≥1500 cells/mm3
    2. Platelet count ≥100,000/mm3
    3. Hemoglobin ≥9 g/dL
    4. INR, activated partial thromboplastin time (aPTT), and prothrombin time (PT) all within 1.2 times the institutional upper limit of normal (ULN) in the absence of any other indicator of liver dysfunction. Patients on anticoagulants are allowed.
    5. Estimated glomerular filtration rate (GFR) ≥45 mL/min
    6. Total bilirubin ≤ULN
  • Aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) ≤1.5 times the institutional ULN. Alkaline phosphatase (ALP) ≤1.5 times ULN unless clearly attributable to a non-hepatic source, e.g., bone metastasis.
  • Albumin ≥3.0 g/dL
  • Able to provide informed consent.

General Exclusion Criteria (for Dose Escalation, Expansion, and UPLIFT) :

  • Major surgery within 28 days of starting study treatment, systemic anti-cancer therapy within the lesser of 28 days or 5 half-lives of the prior therapy before starting study treatment, or recent radiation therapy with unresolved toxicity or within a time window of potential toxicity.
  • Patients with untreated CNS metastases (including new and progressive brain metastases), history of leptomeningeal metastasis or carcinomatous meningitis.
  • Current known active infection with HIV, hepatitis B virus, or hepatitis C virus.
  • No prior history of liver disease such as liver cirrhosis, hepatic fibrosis
  • Current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, or metabolic disease) or intercurrent illness that could interfere with per-protocol evaluations.
  • Severe dyspnea at rest due to complications of advanced malignancy, or requiring supplementary oxygen therapy.
  • Currently active pneumonitis or interstitial lung disease.
  • Pregnant or nursing women.
  • History of other malignancy within the last 2 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or other malignancy with a similar expected curative outcome.
  • Active corneal disease, or history of corneal disease within 12 months prior to enrollment
  • Use of strong CYP450 inhibitors

Ovarian Cancer Inclusion Criteria for UPLIFT:

  • Histological diagnosis of high grade serous ovarian cancer, which includes fallopian tube, or primary peritoneal cancer, that is metastatic or recurrent.
  • Platinum-resistant disease

    1. Patients who have only had 1 line of platinum-based therapy must have received at least 4 cycles of platinum, must have had a response [complete response/remission (CR) or partial response/remission (PR)], and then progressed between 3 months and ≤ 6 months after the date of the last dose of platinum
    2. Patients who have received 2 to 4 lines of prior therapy must have received at least 4 cycles of platinum and then progressed within 6 months after the date of the last dose of platinum
  • One to 4 prior lines of systemic therapy for ovarian cancer

    a. Prior treatment with bevacizumab is required for patients with 1 to 2 prior lines of therapy

  • Patients must be willing to provide an archival tumor tissue block or slides or if not available, undergo procedure to obtain a new tumor biopsy using a low-risk, medically routine procedure

Ovarian Cancer Exclusion Criteria for UPLIFT:

  • Low-grade, clear cell, endometrioid, mucinous, carcinosarcoma, germ-cell, mixed histology, or stromal tumors
  • Prior treatment with mirvetuximab soravtansine or another ADC containing an antitubulin payload
  • Primary platinum-resistant disease, defined by a lack of response or by progression within 3 months after completing front-line, platinum-containing therapy.
  • Participation in DES or EXP segments of this study

Ovarian Cancer Inclusion Criteria for Expansion:

  • Histological diagnosis of high grade serous ovarian cancer, which includes fallopian tube, or primary peritoneal cancer, that is metastatic or recurrent.
  • One to 3 prior lines of systemic therapy for ovarian cancer including at least 1 prior line of a platinum-containing regimen. These patients must have platinum-resistant disease, defined as completing 4 or more cycles of platinum-based therapy and progressing within 6 months of last platinum-based therapy.

    1. Patients with 4 lines of prior systemic therapy regardless of platinum sensitivity status may be enrolled at the Investigator's discretion and upon written approval by the Sponsor Medical Monitor.
    2. Maintenance therapy, e.g., a PARP-inhibitor or bevacizumab given after a platinum-containing regimen, will not count as a separate line of therapy.
  • Tumor sample must be provided from both timepoints.

    1. An archived tumor sample
    2. A recent tumor biopsy (if medically feasible). If a recent biopsy cannot be obtained, enrollment requires written approval by the Sponsor Medical Monitor.

Ovarian Cancer Exclusion Criteria for Expansion:

  • Low-grade, clear cell, endometrioid, mucinous, carcinosarcoma, germ-cell, or stromal tumors
  • Prior treatment with mirvetuximab soravtansine or another ADC containing an auristatin or maytansinoid payload
  • More than 2 prior lines of treatment with a taxane-containing regimen.
  • Primary platinum resistant disease, defined by a lack of response or progression within 3 months after completing front-line, platinum-containing therapy
  • Participation in the dose escalation segment of this study

NSCLC Inclusion Criteria for Expansion:

  • Histological diagnosis of adenocarcinoma NSCLC, that is metastatic or recurrent
  • One prior treatment regimen with a platinum-based therapy and 1 prior treatment regimen with a PD-1 or PD-L1 monoclonal antibody (either in combination or sequentially).

    a. Patients previously treated with immunotherapy will require a washout phase of 4 weeks

  • Patients with known oncogenic mutations for which there are approved therapies e.g., ALK translocation, EGFR mutation, must have received appropriate targeted therapy in addition to a platinum-based regimen. Prior treatment with a PD1/L1 is not required for these patients.
  • One or 2 prior lines of chemotherapy
  • Head CT or MRI within 3 months prior to initiation of screening procedures or may be done during screening

    a. Patients with history of brain metastases must have brain imaging within 4 weeks prior to or during screening

  • Tumor sample must be provided from both timepoints.

    1. An archived tumor sample
    2. A recent tumor biopsy (if medically feasible)

NSCLC Exclusion Criteria for Expansion:

  • Histologies other than adenocarcinoma, e.g., large cell, squamous cell, or adenosquamous
  • Prior treatment with an ADC containing auristatin or maytansinoid payload
  • More than one prior line of immunotherapy
  • Participation in the dose escalation segment of this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03319628


Contacts
Layout table for location contacts
Contact: Azniv Shahverdyan 617-715-8211 ashahverdyan@mersana.com

Locations
Show Show 44 study locations
Sponsors and Collaborators
Mersana Therapeutics
IQVIA Biotech
Investigators
Layout table for investigator information
Study Director: Robert Burger, MD Mersana Therapeutics
Layout table for additonal information
Responsible Party: Mersana Therapeutics
ClinicalTrials.gov Identifier: NCT03319628    
Other Study ID Numbers: XMT-1536-1
First Posted: October 24, 2017    Key Record Dates
Last Update Posted: May 3, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No